Microbiome Immunotherapy Toxicity and Response Evaluation

Lung Cancer Clinical Trial

Official title:

An Observational Study to Evaluate the Microbiome as a Biomarker of Efficacy and Toxicity in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04107168
• Other study ID #: MITRE
• Secondary ID: C7535/A27717
• Status: Recruiting
• Start date: July 8, 2020
• Est. completion date: July 8, 2025

Study information

• Verified date: February 2023
• Source: Cambridge University Hospitals NHS Foundation Trust
• Contact: MITRE Study Coordinator
• Phone: 01223 274746
• Email: cuh.mitre[@]nhs.net
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a observational study to investigate how the microbiome correlates with efficacy and toxicity of immune checkpoint inhibitors in patients with advanced cancer.

Description:

The gastrointestinal microbiome of a healthy individual is comprised of many hundreds of bacteria species and thousands of bacteria strains. The composition of bacteria in an individual's microbiome can change over time and this can be influenced by factors including diet, drugs, genetics and infection. These bacteria play a central role in digestion of food, development and regulation of our immune system as well as our resistance to pathogens. Recent evidence suggest that a patient's intestinal microbiota composition plays a critical, though as yet poorly defined, role in determining both therapeutic efficacy and likelihood of significant adverse events to T-cell checkpoint inhibitor immunotherapy.

Immune checkpoint inhibitors are revolutionising treatment of many types of metastatic cancer, including melanoma, renal and non-small cell lung cancer, in the expectation of improving patient overall survival. However, they have limitations as they do not work for all patients and can cause unpredictable, complex immune-related toxicities. The investigators will perform a detailed study of cancer patients receiving checkpoint inhibitors. Saliva and a series of stool samples will be collected from each patient to analyse their microbiome and will be linked to treatment response, by examining blood samples and - if available - tumour and organ samples. The investigators hope this work will enable personalisation of patient immunotherapies based on microbiome biomarkers, as well as precisely manipulate a patient's microbiota to optimise their immunotherapy.

In addition, participants who have consented to take part in an optional sub-study may be offered a single nasopharyngeal swab for COVID-19 antigen before study entry. The investigators hope that that this identify correlations between the microbiome and COVID-19.

Comparison with a limited cohort of healthy household members (up to 360 volunteers) acting as controls will provide additional essential information about the role of the patient-specific microbiome.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1800
• Est. completion date: July 8, 2025
• Est. primary completion date: July 8, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria for cancer patients:

• Signed informed consent

• Aged =18 years old

• Histological or cytological confirmation of invasive malignancy

• Due to commence palliative, adjuvant or neoadjuvant systemic therapy including an anti-PD-(L)1 antibody +/- anti-CTLA-4 antibody

• Patients with unresectable disease must have radiologically and/or clinically measurable disease, by RECIST version 1.1; target lesions must not have been previously irradiated; baseline tumour assessments must be performed within 45 days prior to starting immune checkpoint inhibitor treatment

• Received no prior immune checkpoint inhibitors (previous treatment with other types of anti-cancer therapy is determined by patient cohort; for patients with unresectable disease, prior adjuvant therapy with immune checkpoint inhibitor(s) is allowed).

• Willing and able to comply with scheduled visits, treatment plans, sample collections and other study procedures

Exclusion Criteria for cancer patients:

• Other invasive malignancies diagnosed within the last year which are not fully resected, or in complete remission, or for which additional therapy is required

• Significant acute or chronic medical or psychiatric condition, disease or laboratory abnormality which in the judgment of the investigator would place the patient at undue risk, or interfere with their ability to comply with the study. Examples may include, but are not limited to:

• Patients with uncontrolled ischaemic heart or other cardiovascular event (e.g. myocardial infarction, new angina, stroke, transient ischaemic attack, or new congestive cardiac failure) within the last 6 months

• Presence of active infection

• Cirrhotic liver disease, known chronic active or acute hepatitis B, or hepatitis C

• Current active, severe, or uncontrolled autoimmune condition, including but not limited to Crohn's disease and ulcerative colitis.

• Women who are pregnant, plan to become pregnant or are lactating during the study period.

• Requirement for non-physiological dose of oral steroids, or regular use of any other immunosuppressive agents; less than 10mg prednisolone or equivalent doses are allowed. Use of inhaled or topical steroids is allowed.

Household control eligibility requirements:

Confirmation of suitability to be a household control participant will be determined by completing a self-assessed questionnaire either at home or in clinic.

Household controls must:

• NOT have had any gastrointestinal infections i.e., parasites, viruses or diarrhoeal episodes during the last 6 months.

• NOT have taken antibiotics for at least 6 months

• NOT have or be recovering from any chronic intestinal disease such as:

• Crohn's disease

• Ulcerative colitis

• Coeliac disease

• Irritable bowel syndrome

• Stomach ulcers

• NOT have a chronic autoimmune disease or significant allergies e.g., multiple sclerosis, asthma requiring regular medication, psoriasis.

• NOT have and NOT be recovering from any form of cancer.

• NOT take proton pump inhibitors, steroids, other non-steroidal anti-inflammatory drugs such as ibuprofen or aspirin.

• NOT had requirement to be hospitalised for treatment of COVID-19

In addition, household controls must sign informed consent and be aged =18 years old.

Related Conditions & MeSH terms

• Kidney Neoplasms
• Lung Cancer
• Melanoma
• Renal Cancer

Intervention

Drug:
• Nivolumab
A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).
• Pembrolizumab
A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.
• Ipilimumab
A human immunoglobulin G1 (IgG1) monoclonal antibody raised against cytotoxic T lymphocyte antigen-4 (CTLA-4).
• Durvalumab
A human immunoglobulin G1-kappa (IgG1-kappa) monoclonal antibody that binds to programmed death ligand 1 (PD-L1).
• Tremelimumab
A fully human monoclonal antibody raised to target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
• Atezolizumab
A humanised IgG1 monoclonal antibody raised to target programmed death-ligand 1 (PD-L1).
• Bevacizumab
A humanised IgG1 monoclonal antibody raised to target vascular endothelial growth factor (VEGF).

Locations

Country	Name	City	State
United Kingdom	Royal United Hospitals Bath NHS Foundation Trust	Bath
United Kingdom	University Hospitals Dorest NHS Foundation Trust	Bournemouth
United Kingdom	University Hospitals Bristol NHS Foundation Trust	Bristol
United Kingdom	Cambridge University Hospitals NHS Foundation Trust	Cambridge
United Kingdom	Velindre University NHS Trust	Cardiff
United Kingdom	Western General Hospital	Edinburgh
United Kingdom	The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust	King's Lynn
United Kingdom	University Hospitals of Leicester NHS Foundation Trust	Leicester
United Kingdom	Norfolk and Norwich University Hospitals NHS Foundation Trust	Norwich
United Kingdom	Sheffield Teaching Hospitals NHS Foundation Trust	Sheffield
United Kingdom	University Hospital Southampton NHS Foundation Trust	Southampton
United Kingdom	Somerset NHS Foundation Trust	Taunton
United Kingdom	Royal Cornwall Hospitals NHS Trust	Truro

Sponsors (2)

Lead Sponsor	Collaborator
CCTU- Cancer Theme	Microbiotica Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Can the microbiome signature predict progression-free survival (PFS) of 1 year or greater	The primary outcome measure is the ability to predict for PFS of 1 year or greater for patients with advanced melanoma, renal and non-small cell lung cancer (cohorts 1-6).	Minimum 1 year PFS
Secondary	Can the microbiome signature predict PFS	Measure the ability of the microbiome signature to predict 6 month PFS, 2 year PFS, overall response rate and median PFS in Cohorts 1-6.	1 year & 2 years PFS
Secondary	Can the microbiome signature overall survival (OS)	Measure the ability of the microbiome signature to median OS in Cohorts 1-6.	Up to 6 years
Secondary	Can the microbiome signature to predict relapse	Measure the ability of the microbiome signature to predict for 1 or 2 year relapse after resection of high risk melanoma or renal cancer in cohorts 7-9.	1 year & 2 years relapse-free survival (RFS)
Secondary	Does the microbiome correlate with treatment efficacy	To compare pre-treatment oral and gut microbiome findings and their association with treatment efficacy.	Up to 6 years
Secondary	Correlate microbiome findings with incidence and characteristics of immune-related adverse events	To correlate microbiome findings with incidence and characteristics of CTCAE V5-defined Grade 3 or greater immune-related adverse events in all enrolled cancer patients, and any association with response to immunosuppressants.	Up to 6 years
Secondary	Correlation microbiome findings and known characteristics of patients	To correlate microbiome findings with aspects of pre-existing patient characteristics and behaviour including but not limited to diet, smoking history, BMI, use of antibiotics, steroids, proton pump inhibitors, non-steroidal anti-inflammatory drugs and probiotics.	Up to 6 years
Secondary	Control for the microbiome of cancer patients	To compare the microbiome signature of cancer patients with a household control group of people who are not known to have cancer.	Up to 6 years
Secondary	Build a library of biological samples for future research	To retain a library of biological samples (saliva, stool, blood and tumour as well as organ if available) with linked patient data for future research.	Up to 6 years